Instrument Inactif

Communiqués Fibrocell Science Inc OTC Bulletin Board

Actions

US3157211000

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

Communiqués

17/12/19	Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science	AQ
13/12/19	FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
10/12/19	FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
22/11/19	FIBROCELL SCIENCE, INC. : Other Events (form 8-K)	AQ
17/09/19	FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC	BU
14/08/19	Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights	GL
29/05/19	Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	GL
15/04/19	Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	GL
27/03/19	Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	GL
06/02/19	Fibrocell to Present at 21st Annual BIO CEO & Investor Conference	GL
16/01/19	Fibrocell to Present at Phacilitate Leaders World 2019	GL
13/11/18	Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights	GL
08/11/18	Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights	GL
25/10/18	Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	GL
29/08/18	Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference	GL
09/08/18	Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights	GL
05/07/18	Fibrocell Announces Closing of $4.0 Million Registered Direct Offering	GL
02/07/18	Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market	GL
31/05/18	Fibrocell Announces Closing of $6.0 Million Registered Direct Offering	GL
29/05/18	Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market	GL